AiMediq at MEDICA 2026
Meet the AiMediq team at our stand in Düsseldorf. Book a meeting for a clinic conversation, a scientific discussion or a partnership.
Hall 11 · Stand H66
Event detailsAbout AiMediq
The people who made medical IHHT® individually doseable
The AiMediq team created medical IHHT® and its individual physiological dosing, then brought both inventions together in the ReOxy® medical device.
Our mission
We bring clinical insight, physiology and medical engineering together to make individually dosed IHHT® usable in clinical practice. We continue to develop the evidence, the technology and the relationships that support that work.
01
History
Milestones, 2005–2026
Two tracks, as in our company history: developing the method and the medical device, and clinical research and European collaboration.
Method and medical device
-
2003
Medical IHHT® conceived
Alexey Platonenko dates the team’s first development work to 2003.
-
2005
IHHT® method
Patent application RU2289432
-
2008
response-guided control
Patent application RU2365384
- 2010
Ai Mediq S.A. established in Luxembourg
Incorporated on 23 July 2010, RCS Luxembourg B155029. The team’s method development began earlier at VNIIMI.
-
2011
ReOxy prototype with Bitmos
- 2012
Four-patent portfolio transferred to AiMediq
Exclusive rights in RU2391121, RU2365384, RU2289432 and RU2414250 were transferred from VNIIMI under the agreement of 24 April 2012, registered on 19 June 2012 as РД0101200.
- 2013–2014
Clinical use, commercial supply and Class IIb declaration
Clinical use and a commercial shipment are documented in 2013. On 24 January 2014, Bitmos signed the Class IIb declaration of conformity for ReOxy 60-1001 and 60-2001 under Directive 93/42/EEC.
-
2015
Intended use in coronary artery disease
Clinical research and European collaboration
- 2009–2020
Clinical research becomes a continuing programme
Early clinical publications were followed by studies explicitly identifying ReOxy. Healthcare professionals and researchers can explore the named studies, their populations and methods in the research programme.
- 2018–2019
Two European Commission Seals of Excellence
AiMediq’s ReOxy proposals received Seals of Excellence under Horizon 2020 SME Instrument Phase 1. Proposal 854544 scored 13.01/15; proposal 868607 scored 13.50/15. Certificates were issued on 17 December 2018 and 28 March 2019.
The Seals recognise the quality of the proposals. They are not clinical-efficacy certification or a funding award.
- 2019–2020
ReOxy4Heart: a European research consortium
Ten organisations across six countries submitted a Horizon 2020 proposal in 2019 to study personalised IHHT in people with heart failure. The proposal was evaluated in 2020 and was not funded. The planned trial is distinct from completed ReOxy studies.
- 2026
Advancing an established clinical research programme
AiMediq continues the ReOxy-specific clinical programme and welcomes collaborators to develop the next research questions, protocols and outcome measures. Discuss a research project.
-
2026
MEDICA 2026, Düsseldorf
Our own stand, 16–19 November 2026. Event details
02
Team
The people behind AiMediq
Who leads the company and whom to contact for clinics, research and partnerships.
-
Managing Director
Dr Alexey Platonenko, MBA
Dr Alexey Platonenko is Managing Director of Ai Mediq S.A. His work connects clinical practice, physiological research and medical-device development. He is a named inventor in the 2008 response-guided control patent records and a co-author of the team’s 2010 clinical publication.
Contact management
Tell us whether your request concerns clinical information, research, distribution or technical support. Contact the relevant team.
Built through international scientific collaboration
AiMediq has brought clinical researchers and medical specialists into the development of physiologically dosed IHHT®. Documented contributions include scientific advisory work, clinical-protocol development and letters supporting further research into ReOxy's potential.
In 2019, AiMediq helped assemble a European research consortium that submitted ReOxy4Heart to Horizon 2020, involving 10 organisations across six countries. The proposed randomised study asked whether personalised IHHT could improve functional capacity and well-being in people with heart failure. Its draft clinical protocol had been approved by John G. F. Cleland and Maurizio Volterrani. The proposal was not funded. This is a historical research proposal, not a completed study or a new statement of the current device’s intended use.
-
University of Glasgow
John G. F. Cleland
Scientific advisory agreement (2016); approval of the draft ReOxy4Heart clinical protocol (2019).
-
Charité – Universitätsmedizin Berlin
Wolfram Doehner
Letter confirming continued collaboration and a proposed advisory role (24 October 2018).
-
San Raffaele Roma
Maurizio Volterrani
Coordinator and clinical-protocol lead for the ReOxy4Heart proposal (2019); letter of support (2018).
-
University of Milano-Bicocca · Istituto Auxologico Italiano
Gianfranco Parati
Letter supporting further research and a proposed advisory role (24 October 2018).
-
Hermann Buhl Institut
Nikolaus Netzer
Letter supporting further research (24 October 2018); named contact in the ReOxy4Heart proposal (2019).
-
Istituti Clinici Scientifici Maugeri
Roberto Franco Pedretti
Named cardiological-rehabilitation contact in the ReOxy4Heart proposal (2019).
ReOxy4Heart proposal (2019): San Raffaele Roma (coordinator) · Istituti Clinici Scientifici Maugeri · Charité – Universitätsmedizin Berlin (Frank Edelmann) · Salzburger Landeskliniken (Josef Niebauer) · Hermann Buhl Institut · Luxembourg Institute of Health · Associação para Investigação e Desenvolvimento da Faculdade de Medicina · University of Glasgow · Centre Hospitalier de Luxembourg · Ai Mediq S.A. Roles are those at the time of the proposal.
These are documented historical contributions. Affiliations and roles refer to the stated dates; they do not constitute a current Scientific Advisory Board roster or institutional endorsement.
Clinical experience became a medical method
ReOxy grew from its creators’ work in clinical practice, physiology and medical programmes. The team connected that experience with a concrete problem: how to determine and control the individual physiological load of hypoxic–hyperoxic treatment.
The 2005 method patent names Yuri V. Arkhipenko, Tatyana G. Sazontova, Oleg S. Glazachev and Viacheslav I. Platonenko. The 2008 response-guided control applications name Alexander I. Kostin, Oleg S. Glazachev, Alexey V. Platonenko and Galina K. Spirina. The work began at VNIIMI and continued through AiMediq’s medical-device and clinical research programme.
The clinical question behind ReOxy: Alexey Platonenko’s account
03
Quality and manufacturing
Engineering, manufacturing and quality
Purpose-designed for ReOxy®
Three processors.
Hardware-separated functions.
Three-level, three-processor architecture with redundant hardware-separated measurement, multi-valve-dosing (instant-mixing technology) and safety control.
SRT® treatment control
A dedicated embedded controller runs SRT® based on 10 different internal sensor measurements.
More than 90% of components have been specifically designed for the ReOxy® medical device.
Explore the ReOxy engineering-
01
Medical-device engineering
AiMediq's dosing principle became ReOxy® through medical-device engineering with Bitmos — respiratory technology, patient monitoring and medical software. Gas-system performance and quality are checked in a dedicated test facility, separate from assembly.
-
02
Manufacturing and quality system
Manufactured in Germany: ReOxy® is serially manufactured by Bitmos GmbH, Düsseldorf. Bitmos' quality management system is certified to EN ISO 13485:2016 by TÜV Rheinland (SX 1010072-1).
-
03
Regulatory information
- Intended use
- Intended use: improvement of physical exercise capacity in adult and senior patients with coronary artery disease (CAD).
- Conditions of use
- For use in a clinical environment under professional supervision and according to a doctor's prescription.
- Instructions for Use
- See the Instructions for Use for contraindications, warnings and precautions. Instructions for Use (HCP)
- Availability
- Availability varies by country.
- Manufacturer
- Bitmos GmbH, Himmelgeister Str. 37, 40225 Düsseldorf, Germany
-
04
Vigilance
To report a side effect, an incident or a complaint related to ReOxy®, please write to [email protected].
Documents
- Instructions for Use HCP login
-
Regulatory documents
04
Patents and trademarks
Patents
The AiMediq team began developing medical IHHT® at VNIIMI before Ai Mediq S.A. was incorporated in Luxembourg in 2010. The documented sequence includes the 2005 method application, the 2008 response-guided control applications and the later European patent EP 3 452 154 B1.
-
European patent
EP 3 452 154 B1
Response-guided exposure and recovery
European Patent Register -
Patent portfolio
2005 · 2008
First patent filings. Application numbers are listed in our history.
In 2012, VNIIMI transferred exclusive rights in RU2391121, RU2365384, RU2289432 and RU2414250 to Ai Mediq S.A. The registered transfer is part of the documented history; current enforceability is a separate territorial question.
-
Trademarks
ReOxy® · IHHT® · SRT®
ReOxy®, IHHT® and SRT® are registered trade marks of Ai Mediq S.A. The European Union registrations are ReOxy 010659142, IHHT 010752616 and SRT 010659159.
The company’s trade-mark register dated 13 February 2026 records corresponding UK registrations. Territorial protection is specific to each mark and jurisdiction.
Patent records describe technical inventions. Clinical results are reported separately in the research programme.
06
Investors
Investor information
Ai Mediq S.A. is based in Luxembourg. For investor enquiries, please contact the management.
07
Contact
Address and contact
Use the contact page to reach the right team: clinics, healthcare professionals, researchers, distribution partners, press or investors.